Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$51.21
-2.6%
$48.54
$21.72
$54.60
$10.06B1.252.19 million shs2.09 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$23.51
-7.4%
$28.34
$23.15
$75.37
$9.88B1.939.75 million shs31.22 million shs
Organon & Co. stock logo
OGN
Organon & Co.
$10.65
-0.1%
$9.64
$8.01
$21.06
$2.77B0.63.50 million shs2.70 million shs
QIAGEN N.V. stock logo
QGEN
QIAGEN
$45.30
-1.7%
$48.47
$37.63
$51.88
$10.24B0.641.32 million shs992,179 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-0.68%+1.49%+7.15%+32.23%+87.92%
Moderna, Inc. stock logo
MRNA
Moderna
+4.44%+4.57%-1.05%-4.80%-68.07%
Organon & Co. stock logo
OGN
Organon & Co.
+3.86%+10.24%+17.92%+6.33%-47.12%
QIAGEN N.V. stock logo
QGEN
QIAGEN
0.00%-2.00%-5.96%-2.16%+3.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$51.21
-2.6%
$48.54
$21.72
$54.60
$10.06B1.252.19 million shs2.09 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$23.51
-7.4%
$28.34
$23.15
$75.37
$9.88B1.939.75 million shs31.22 million shs
Organon & Co. stock logo
OGN
Organon & Co.
$10.65
-0.1%
$9.64
$8.01
$21.06
$2.77B0.63.50 million shs2.70 million shs
QIAGEN N.V. stock logo
QGEN
QIAGEN
$45.30
-1.7%
$48.47
$37.63
$51.88
$10.24B0.641.32 million shs992,179 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-0.68%+1.49%+7.15%+32.23%+87.92%
Moderna, Inc. stock logo
MRNA
Moderna
+4.44%+4.57%-1.05%-4.80%-68.07%
Organon & Co. stock logo
OGN
Organon & Co.
+3.86%+10.24%+17.92%+6.33%-47.12%
QIAGEN N.V. stock logo
QGEN
QIAGEN
0.00%-2.00%-5.96%-2.16%+3.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
3.00
Buy$63.9424.86% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$42.8882.40% Upside
Organon & Co. stock logo
OGN
Organon & Co.
2.80
Moderate Buy$17.3362.75% Upside
QIAGEN N.V. stock logo
QGEN
QIAGEN
2.27
Hold$49.699.68% Upside

Current Analyst Ratings Breakdown

Latest OGN, QGEN, BBIO, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/12/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$72.00 ➝ $82.00
9/3/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$55.00 ➝ $70.00
8/29/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$56.00 ➝ $70.00
8/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetUnderperform$18.00 ➝ $15.00
8/7/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
8/7/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$48.00 ➝ $50.00
8/6/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSector Outperform$55.00 ➝ $57.00
8/6/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$60.00 ➝ $61.00
8/4/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$40.00 ➝ $31.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$32.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$26.00
(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$221.90M44.12N/AN/A($7.71) per share-6.64
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B2.83N/AN/A$28.33 per share0.83
Organon & Co. stock logo
OGN
Organon & Co.
$6.40B0.43$4.93 per share2.16$1.83 per share5.82
QIAGEN N.V. stock logo
QGEN
QIAGEN
$1.98B5.09$3.15 per share14.37$16.05 per share2.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$535.76M-$4.09N/AN/AN/A-329.25%N/A-85.69%11/11/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$7.53N/AN/AN/A-94.31%-25.96%-20.09%11/6/2025 (Estimated)
Organon & Co. stock logo
OGN
Organon & Co.
$864M$2.693.962.850.9711.15%163.88%6.99%10/30/2025 (Estimated)
QIAGEN N.V. stock logo
QGEN
QIAGEN
$83.59M$1.6926.7618.412.4318.30%14.77%8.87%11/5/2025 (Estimated)

Latest OGN, QGEN, BBIO, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.83-$0.95-$0.12-$0.95$98.46 million$110.57 million
8/5/2025Q2 2025
Organon & Co. stock logo
OGN
Organon & Co.
$0.94$1.00+$0.06$0.56$1.55 billion$1.59 billion
8/5/2025Q2 2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.60$0.60N/A$0.44$523.97 million$533.54 million
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Organon & Co. stock logo
OGN
Organon & Co.
$0.080.75%N/A2.97%N/A
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.250.55%N/A14.79%N/A

Latest OGN, QGEN, BBIO, and MRNA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/5/2025
Organon & Co. stock logo
OGN
Organon & Co.
quarterly$0.020.9%8/15/20258/15/20259/11/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
5.19
5.08
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.93
3.77
Organon & Co. stock logo
OGN
Organon & Co.
11.98
1.65
1.13
QIAGEN N.V. stock logo
QGEN
QIAGEN
0.25
1.61
1.35

Institutional Ownership

CompanyInstitutional Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Organon & Co. stock logo
OGN
Organon & Co.
77.43%
QIAGEN N.V. stock logo
QGEN
QIAGEN
70.00%

Insider Ownership

CompanyInsider Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
18.20%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Organon & Co. stock logo
OGN
Organon & Co.
1.96%
QIAGEN N.V. stock logo
QGEN
QIAGEN
9.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400191.17 million156.38 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800389.08 million346.28 millionOptionable
Organon & Co. stock logo
OGN
Organon & Co.
4,000259.97 million254.87 millionNot Optionable
QIAGEN N.V. stock logo
QGEN
QIAGEN
5,765222.29 million202.29 millionOptionable

Recent News About These Companies

Financial Comparison: QIAGEN (NYSE:QGEN) and Polyrizon (NASDAQ:PLRZ)
7 Hot Healthcare Stocks To Buy Right Now
Qiagen N.V. Announces Voting Rights Notification
Qiagen N.V. $QGEN Shares Sold by Amundi
PDT Partners LLC Trims Stake in Qiagen N.V. $QGEN

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$51.21 -1.39 (-2.64%)
Closing price 04:00 PM Eastern
Extended Trading
$52.71 +1.50 (+2.93%)
As of 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Moderna stock logo

Moderna NASDAQ:MRNA

$23.51 -1.88 (-7.40%)
Closing price 04:00 PM Eastern
Extended Trading
$23.64 +0.13 (+0.57%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Organon & Co. stock logo

Organon & Co. NYSE:OGN

$10.65 -0.01 (-0.09%)
Closing price 03:59 PM Eastern
Extended Trading
$10.68 +0.03 (+0.28%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

QIAGEN stock logo

QIAGEN NYSE:QGEN

$45.30 -0.76 (-1.65%)
Closing price 03:59 PM Eastern
Extended Trading
$45.29 -0.01 (-0.02%)
As of 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.